# Zerigo Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zerigo-health

- Industry: Medical Devices & Equipment
- Headquarters: San Diego, US
- Website: www.zerigohealth.com
- Total disclosed funding: $61M
- Latest round: Series B (Oct 6, 2021)
- Investors on record: 10

## About

Zerigo Health, Inc. is a US-based healthcare company specializing in innovative phototherapy solutions for chronic skin conditions, providing users with convenient treatment options both at home and in clinical settings.Founded in 2014 and headquartered in San Diego, US, Zerigo Health, Inc. develops a portable device that uses narrowband UVB phototherapy for treating chronic skin diseases. The company successfully raised USD 43.00 mn in Series B funding in October 2021, led by 7wireVentures and supported by notable investors including Bluestem Capital Company and Cigna Ventures. This funding aims to strengthen their market reach in the health plan and self-insured employer sector.Zerigo Health's primary offering is a portable, handheld device that utilizes narrowband UVB phototherapy to treat chronic skin conditions such as psoriasis, eczema, and vitiligo. This FDA-cleared phototherapy system allows users to conduct treatments conveniently at home or in clinical settings. The associated Zerigo App employs machine learning to personalize treatment plans, track patient progress, and maintain connectivity with Care Guides who provide support throughout the treatment journey, catering to individual patients and health plans.Zerigo Health generates revenue through a subscription-based model that grants individuals and health plans access to its phototherapy device along with personalized treatment support via the Zerigo App. Clients typically enter agreements for the device, which includes ongoing consultations with licensed providers for diagnosis and therapy adjustments, fostering long-term relationships that secure a steady revenue stream within the healthcare market.In October 2021, Zerigo Health raised USD 43.00 mn in Series B funding to support its next phase of growth and expand its market reach. The company plans to enhance its product offerings and explore new geographic markets while strengthening its position in the health plan and self-insured employer sector. The recent funding will be utilized to support these initiatives and further develop their innovative solutions for chronic skin condition management.

## Funding rounds

- Series B, Oct 6, 2021, $43M — Bluestem Capital Company, General Catalyst Partners, SV Health Investors, H.I.G. BioHealth Partners, 7wireVentures, Dragoneer Investment Group, Cigna Ventures, Leaps by Bayer, Leverage Health
- Series A, Oct 23, 2019, $18M — Bluestem Capital Company, SV Health Investors, H.I.G. BioHealth Partners, 7wireVentures
- Series A, Apr 22, 2016, $0.4M — Serra Ventures

## Investors

- Serra Ventures (https://capitalatlas.ai/funds/serra-ventures) — Series A
- Bluestem Capital Company (https://capitalatlas.ai/funds/bluestem-capital-company) — Series A, Series B
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A, Series B
- H.I.G. BioHealth Partners (https://capitalatlas.ai/funds/h-i-g-biohealth-partners) — Series A, Series B
- 7wireVentures (https://capitalatlas.ai/funds/7wireventures) — Series A, Series B
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series B
- Dragoneer Investment Group (https://capitalatlas.ai/funds/dragoneer-investment-group) — Series B
- Cigna Ventures (https://capitalatlas.ai/funds/cigna-ventures) — Series B
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series B
- Leverage Health (https://capitalatlas.ai/funds/leverage-health) — Series B